The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
 
Tara Beth Sanft
Consulting or Advisory Role - bioTheranostics
Research Funding - bioTheranostics (Inst)
 
Bilge Aktas
No Relationships to Disclose
 
Brock Schroeder
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics
Patents, Royalties, Other Intellectual Property - bioTheranostics
 
Veerle Bossuyt
No Relationships to Disclose
 
Michael DiGiovanna
No Relationships to Disclose
 
Maysa M. Abu-Khalaf
Research Funding - Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Gina G. Chung
No Relationships to Disclose
 
Andrea Silber
Speakers' Bureau - Novartis
 
Erin Wysong Hofstatter
No Relationships to Disclose
 
Sarah Schellhorn Mougalian
Stock and Other Ownership Interests - Coronado Biosciences; Gilead Sciences; Roche
Research Funding - Genentech
 
Lianne Epstein
Speakers' Bureau - Supernus Pharmaceuticals (I)
 
Christos Hatzis
Stock and Other Ownership Interests - Nuvera Biosciences
 
Catherine A. Schnabel
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics
Patents, Royalties, Other Intellectual Property - bioTheranostics
 
Lajos Pusztai
Honoraria - BioTheranostics; Pfizer
Consulting or Advisory Role - Celgene; Clovis Oncology
Research Funding - Foundation Medicine; Genentech; Merck